American Journal of Cardiovascular Drugs

Does Ischemic Preconditioning Afford Clinically Relevant Cardioprotection?
pp. 1-11(11)
Authors: Mikhail P.; Verma S.; Fedak P.W.M.; Weisel R.D.; Li R-K.

Vasopressin Receptor Antagonists: Therapeutic Potential in the Management of Acute and Chronic Heart Failure
pp. 13-20(8)
Authors: Russell S.D.; DeWald T.

Hypertensive Emergencies: Etiology and Management
pp. 21-31(11)
Authors: Tuncel M.; Ram V.C.S.

Defining the Role of Calcium Channel Antagonists in Heart Failure Due to Systolic Dysfunction
pp. 33-41(9)
Authors: Mahé I.; Chassany O.; Grenard A-S.; Caulin C.; Bergmann J-F.

Photopheresis: Therapeutic Potential in Preventing Restenosis After Percutaneous Transluminal Coronary Angioplasty
pp. 43-51(9)
Authors: Bisaccia E.; Palangio M.; Gonzalez J.; Klainer A.S.; Banas J.S.

Optimal Therapy of Low Levels of High Density Lipoprotein-Cholesterol
pp. 53-65(13)
Authors: Kashyap M.L.; Tavintharan S.; Kamanna V.S.

Ezetimibe
pp. 67-76(10)
Authors: Darkes M.J.M.; Poole R.M.; Goa K.L.

Ezetimibe: A Viewpoint by Anthony S. Wierzbicki
pp. 77-78(2)
Author: Wierzbicki A.S.

Ezetimibe: A Viewpoint by Harold Bays
pp. 77-78(2)
Author: Bays H.

Ezetimibe: A Viewpoint by Tatu A. Miettinen
pp. 77-78(2)
Author: Miettinen T.A.